Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FENOFIBRATE

All products: not a benefit

Other products in the same Health Canada class (C10A, C10AB) — coverage varies; not interchangeable

  • Bezafibrate (Bezalip): general benefit
  • Gemfibrozil (Lopid): general benefit, Not a benefit
  • Clofibrate (Atromid-S): not a benefit
  • Atorvastatin (Lipitor): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, Not a benefit
  • Colesevelam (Lodalis): general benefit, Listing status unconfirmed

9 more in the class list below

Sandoz Fenofibrate S · DIN 02288044 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.Discontinued 2020-12-31 · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Fenofibrate S · DIN 02288044 Manufacturer: Sandoz Canada Inc.; listing date 2009-08-18 Health Canada: Cancelled post market since 2020-12-31 · brand SANDOZ FENOFIBRATE S · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 100 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77343 · Verify on the e-Formulary ↗ (DIN 02288044)

Source record
DIN 02288044: Sandoz Fenofibrate S Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240600046; group id 303; item number 0660; lccId None; manufacturer id SDZ Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7874; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02288044 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77343
Interchangeable products
AA-Feno-Super · DIN 02246859 · not recorded Lipidil Supra · DIN 02241601 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2020-12-31 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

CLOFIBRATE

· 2 products · Listed, not a benefit · strengths: 500mg · Cap

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE FENOFIBRATE (fenofibrate, non-micronized formulation) and AA-FENO-MICRO (fenofibrate, micronized formulation) are indicated as an adjunct to diet and other therapeutic measures for: Page 3 of 37 1) Treatment of patients with hypercholesterolemia, Fredrickson classification Types IIa and IIb mixed hyperlipidemias, to regulate lipid levels (reduce serum triglycerides and LDL cholesterol levels and increase HDL cholesterol). 2) Treatment of adult patients with very high serum triglyceride levels, Fredrickson classification Type IV and Type V hyperlipidemias, who are at a high risk of sequelae and complications (i.e., pancreatitis) from their hyperlipidemia. FENOFIBRATE and AA-FENO-MICRO alone may not be adequate therapy in some patients with familial combined hyperlipidemia with Type IIb and Type IV hyperlipoproteinemia. Initial therapy for hyperlipidemia should include a specific diet (at least equivalent to the American Heart Association (AHA) Step I diet), weight reduction, and… https://pdf.hres.ca/dpd_pm/00053567.PDF PM date: not printed or not captured Source product: AA-FENO-MICRO; DIN 02239864; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Sandoz Fenofibrate S: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026